These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37777579)

  • 1. DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells.
    Vanderlinden A; Jones CG; Myers KN; Rominiyi O; Collis SJ
    Br J Cancer; 2023 Nov; 129(11):1829-1840. PubMed ID: 37777579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Optimisation of Tumour Treating Fields (TTFields) Delivery within 3D Primary Glioma Stem Cell-like Models of Spatial Heterogeneity.
    Jones CG; Vanderlinden A; Rominiyi O; Collis SJ
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells.
    Giladi M; Munster M; Schneiderman RS; Voloshin T; Porat Y; Blat R; Zielinska-Chomej K; Hååg P; Bomzon Z; Kirson ED; Weinberg U; Viktorsson K; Lewensohn R; Palti Y
    Radiat Oncol; 2017 Dec; 12(1):206. PubMed ID: 29284495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy.
    Karanam NK; Ding L; Aroumougame A; Story MD
    Transl Res; 2020 Mar; 217():33-46. PubMed ID: 31707040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells.
    Ahmed SU; Carruthers R; Gilmour L; Yildirim S; Watts C; Chalmers AJ
    Cancer Res; 2015 Oct; 75(20):4416-28. PubMed ID: 26282173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines.
    Karanam NK; Srinivasan K; Ding L; Sishc B; Saha D; Story MD
    Cell Death Dis; 2017 Mar; 8(3):e2711. PubMed ID: 28358361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological activity of tumor-treating fields in preclinical glioma models.
    Silginer M; Weller M; Stupp R; Roth P
    Cell Death Dis; 2017 Apr; 8(4):e2753. PubMed ID: 28425987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications.
    Karanam NK; Story MD
    Int J Radiat Biol; 2021; 97(8):1044-1054. PubMed ID: 33086019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.
    Connelly J; Hormigo A; Mohilie N; Hu J; Chaudhry A; Blondin N
    BMC Cancer; 2016 Nov; 16(1):842. PubMed ID: 27809808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour treating fields in a combinational therapeutic approach.
    Branter J; Basu S; Smith S
    Oncotarget; 2018 Nov; 9(93):36631-36644. PubMed ID: 30564303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment.
    DesJarlais AM; Miller R; Ali AS; Niazi MZ; Cappelli L; Glass J; Farrell CJ; Shi W
    Chin Clin Oncol; 2023 Dec; 12(6):69. PubMed ID: 38195076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
    Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
    J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial.
    Guberina N; Pöttgen C; Kebir S; Lazaridis L; Scharmberg C; Lübcke W; Niessen M; Guberina M; Scheffler B; Jendrossek V; Jabbarli R; Pierscianek D; Sure U; Schmidt T; Oster C; Hau P; Grosu AL; Stuschke M; Glas M; Nour Y; Lüdemann L
    Radiat Oncol; 2020 Apr; 15(1):83. PubMed ID: 32307022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor treating fields: a comprehensive overview of the underlying molecular mechanism.
    Hong P; Kudulaiti N; Wu S; Nie J; Zhuang D
    Expert Rev Mol Diagn; 2022 Jan; 22(1):19-28. PubMed ID: 34883030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can tumor treating fields induce DNA damage and reduce cell motility in medulloblastoma cell lines?
    Nitta RT; Luo EJ; Lim M; Li G
    J Neurosurg Pediatr; 2022 Dec; 30(6):555-566. PubMed ID: 36208441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
    Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
    Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
    Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
    J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.
    Rominiyi O; Collis SJ
    Mol Oncol; 2022 Jan; 16(1):11-41. PubMed ID: 34036721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields).
    Shteingauz A; Porat Y; Voloshin T; Schneiderman RS; Munster M; Zeevi E; Kaynan N; Gotlib K; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
    Cell Death Dis; 2018 Oct; 9(11):1074. PubMed ID: 30341282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The EP3-ZNF488 Axis Promotes Self-Renewal of Glioma Stem-like Cells to Induce Resistance to Tumor Treating Fields.
    Chen D; Le SB; Manektalia H; Liu T; Hutchinson TE; O'Dell A; Salhia B; Tran DD
    Cancer Res; 2024 Oct; ():. PubMed ID: 39412953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.